Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
- Conditions
- Prostate Cancer
- Registration Number
- NCT00345293
- Lead Sponsor
- Rockefeller University
- Brief Summary
The purpose of this study is to assess the safety and activity of DC/PC3, a dendritic cell vaccine used as immunotherapy for prostate cancer. The vaccine is made with each participants' own immune cells obtained through blood donation. Dendritic cells are known to activate other immune cells such as T cells, that are able to mount an attack against cancer cells. The dendritic cell vaccine will be administered as injections every 2 weeks over a course of 2 months.
- Detailed Description
See Brief Summary.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 13
Prostate cancer
Rising prostate specific antigen (PSA, 3 values, each measured at least 2 weeks apart) post initial therapy (ie, radiation, prostatectomy) human leukocyte antigen A2.1 (HLA-A2.1)
central nervous system metastasis
History of autoimmune disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Toxicity through week 29 adverse events
- Secondary Outcome Measures
Name Time Method Clinical Response Post treatment Immunogenicity pre and post treatment The Tritiated thymidine proliferation assay is used to assess samples collected pre-treatment and those collected post-treatment; the outcome measure is the change in counts per minute (post-treatment counts minus pre-treatment counts).
Trial Locations
- Locations (1)
Rockefeller University Hospital
🇺🇸New York, New York, United States
Rockefeller University Hospital🇺🇸New York, New York, United States